12/2
06:16 am
avir
Atea Pharmaceuticals (NASDAQ:AVIR) was upgraded by analysts at Evercore ISI to a "strong-buy" rating.
Low
Report
Atea Pharmaceuticals (NASDAQ:AVIR) was upgraded by analysts at Evercore ISI to a "strong-buy" rating.
11/19
08:26 pm
avir
Atea Pharmaceuticals Inc (AVIR) Q3 2025 Earnings Call Highlights: Strategic Advances in HCV ... [Yahoo! Finance]
Medium
Report
Atea Pharmaceuticals Inc (AVIR) Q3 2025 Earnings Call Highlights: Strategic Advances in HCV ... [Yahoo! Finance]
11/19
07:00 am
avir
Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference
Medium
Report
Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference
11/13
02:33 pm
avir
Atea Pharmaceuticals, Inc. (AVIR) Discusses Next-Generation Hepatitis C Treatment Developments and Clinical Advancements Transcript [Seeking Alpha]
Low
Report
Atea Pharmaceuticals, Inc. (AVIR) Discusses Next-Generation Hepatitis C Treatment Developments and Clinical Advancements Transcript [Seeking Alpha]
11/12
07:03 pm
avir
Atea Pharmaceuticals, Inc. (AVIR) Q3 2025 Earnings Call Transcript [Seeking Alpha]
High
Report
Atea Pharmaceuticals, Inc. (AVIR) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/12
04:36 pm
avir
Atea Pharmaceuticals GAAP EPS of -$0.53 misses by $0.09 [Seeking Alpha]
High
Report
Atea Pharmaceuticals GAAP EPS of -$0.53 misses by $0.09 [Seeking Alpha]
11/12
04:05 pm
avir
Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Medium
Report
Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
11/7
08:00 am
avir
Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025
Low
Report
Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025
11/5
07:00 am
avir
Atea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025
Low
Report
Atea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025
10/24
12:16 pm
avir
Atea Pharmaceuticals (NASDAQ:AVIR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Atea Pharmaceuticals (NASDAQ:AVIR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/22
07:00 am
avir
Atea Pharmaceuticals to Host Virtual HCV KOL Panel Event on November 13, 2025
Low
Report
Atea Pharmaceuticals to Host Virtual HCV KOL Panel Event on November 13, 2025
10/7
08:07 am
avir
Atea Pharmaceuticals to Present New Data Supporting Combination of Bemnifosbuvir and Ruzasvir as Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025 [Yahoo! Finance]
Low
Report
Atea Pharmaceuticals to Present New Data Supporting Combination of Bemnifosbuvir and Ruzasvir as Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025 [Yahoo! Finance]
10/7
08:00 am
avir
Atea Pharmaceuticals to Present New Data Supporting Combination of Bemnifosbuvir and Ruzasvir as Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025
Medium
Report
Atea Pharmaceuticals to Present New Data Supporting Combination of Bemnifosbuvir and Ruzasvir as Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025
10/3
03:30 pm
avir
Atea Pharmaceuticals (NASDAQ:AVIR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Atea Pharmaceuticals (NASDAQ:AVIR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.